Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohnʼs Disease
Jean‐Frédéric Colombel(Mount Sinai Hospital), Brian G. Feagan(Western University), Remo Panaccione(University of Calgary), Stephen B. Hanauer(Northwestern University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Silvio Danese(IRCCS Ospedale San Raffaele), Geert D’Haens(Amsterdam University Medical Centers), Serap Sankoh(Millennium Engineering and Integration (United States)), Catherine Milch(Millennium Engineering and Integration (United States)), Asit Parikh, Irving H. Fox(Takeda (United States))
Cited by 22
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k